Pharma Execs Say Senate Drug Pricing Bill Targets Industry, Not The Problem

Industry CEOs expressed reservations about the US drug pricing legislation in the Senate, but said they support reforms that will impact patient affordability, during Q2 calls. 

The United States Capitol building in Washington DC, USA - after dark with water reflection - Image

Industry leaders provided their first public reaction to the new drug pricing bill being debated in the US Senate during second quarter sales and earnings calls on 24 and 25 July. Executives said they are anxiously awaiting more details on what will materialize from ongoing Senate negotiations over the Prescription Drug Pricing Reduction Act of 2019, and that while they have reservations, they support reforms that would improve the affordability of drugs for patients.

The Senate bill, which includes various changes to the way drugs are paid for under Medicare and Medicaid – including...

More from Drug Pricing

More from Scrip